Loading...
•
Jun 30
Jaguar Health Q2 2025 Earnings Report
Jaguar Health reported Q2 2025 results with $3.0 million in revenue, up 35% from Q1, and strong performance from prescription products including Mytesi.
Key Takeaways
Jaguar Health delivered approximately $3.0 million in Q2 2025 revenue, driven by strength in its prescription products portfolio. Despite the revenue increase, the company posted a net loss of $10.4 million and an operating loss of $8.0 million. Mytesi prescriptions rose 6.5% sequentially, and licensing revenues added modest contributions.
Net revenue for Q2 2025 was approximately $3.0 million, up 35% QoQ.
Net loss was $10.4 million, or $(10.25) per share.
Mytesi prescription volume increased 6.5% vs. Q1 2025.
Non-GAAP recurring EBITDA was a loss of $7.9 million, improved from $8.8 million YoY.
Jaguar Health
Jaguar Health
Jaguar Health Revenue by Segment
Revenue by Segment
Human Health Revenue
CapyFin.com Forward Guidance
Jaguar Health plans to pursue licensing partnerships and regulatory progress for crofelemer, with expectations for non-dilutive funding and continued prescription growth.
Positive Outlook
- Mytesi prescription volume grew 6.5% QoQ.
- Crofelemer trials in rare disease settings show early promise.
- License fee revenue contributed positively.
- Company is pursuing non-dilutive licensing deals.
- Non-GAAP recurring EBITDA loss narrowed YoY.
Challenges Ahead
- Net loss widened to $10.4 million.
- Operating loss increased to $8.0 million.
- Cost of product revenue rose with increased Mytesi sales.
- Sales & marketing expenses increased $1.0 million YoY.
- G&A expenses rose due to legal and compliance costs.